Retrospective observational study of Carotegrast methyl investigating efficacy and safety

Retrospective observational study of Carotegrast methyl investigating efficacy and safety - Retrospective observational study of Carotegrast methyl investigating efficacy and safety

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052186

Enrollment

Registered

2023-09-12

Start date

2023-09-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis (UC) patients treated with Carotegrast methyl from May 2022 to December 2022

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with inadequate response or intolerance to treatment with 5-ASA 2) Patients with moderately active UC (any disease type)

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Endoscopic remission rate (Mayo endoscopy score 0, 1 defined as remission)	—

Secondary

Measure	Time frame
- Incidence of side effects - duration of a drug administration - Endoscopic Image Evaluation - Changes in Mayo Scores - Changes in CAI Scores - Changes in frequency of defecation, diarrhea, presence of bloody stools, and abdominal pain - Comparison of background information between cases that achieved remission and those that did not (cases of remission achieved) - Use of Remission Maintenance Therapy Medications, Relapse or Not, Time to Relapse, Medications and Their Efficacy at Relapse, and Transition Rate to Advanced Therapy (Non-achievers in remission) - Therapy and its efficacy after administration of Carotegrast methyl	—

Measure

Time frame

- Incidence of side effects - duration of a drug administration - Endoscopic Image Evaluation - Changes in Mayo Scores - Changes in CAI Scores - Changes in frequency of defecation, diarrhea, presence of bloody stools, and abdominal pain - Comparison of background information between cases that achieved remission and those that did not (cases of remission achieved) - Use of Remission Maintenance Therapy Medications, Relapse or Not, Time to Relapse, Medications and Their Efficacy at Relapse, and Transition Rate to Advanced Therapy (Non-achievers in remission) - Therapy and its efficacy after administration of Carotegrast methyl

—

Countries

Japan

Contacts

Public ContactToshihide Ohmori

Ohmori Toshihide gastro-intestinal Clinic director

toshihideo@gmail.com048-778-4567

Outcome results